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Circulating adiponectin and leptin 
and risk of overall and aggressive 
prostate cancer: a systematic 
review and meta‑analysis
Anya J. Burton1*, Rebecca Gilbert2, Kate Tilling2, Ryan Langdon2, Jenny L. Donovan2, 
Jeff M. P. Holly1 & Richard M. Martin2,3
Obesity is associated with an increased risk of advanced, recurrent and fatal prostate cancer. 
Adipokines may mediate this relationship. We conducted a systematic review and meta‑analysis 
of associations of leptin and adiponectin with overall and aggressive prostate cancer. Bibliographic 
databases were systematically searched up to 1st April 2017. Log Odds Ratios (ORs) per 2.5 unit 
increase in adiponectin or leptin levels were derived and pooled. All analyses were stratified by study 
type (cross‑sectional/prospective). 746 papers were retrieved, 34 eligible studies identified, 31 of these 
could be included in the meta‑analysis. Leptin was not consistently associated with overall prostate 
cancer (pooled OR 1.00, 95%CI 0.98–1.02, per 2.5 ng/ml increase, prospective study OR 0.97, 95%CI 
0.95–0.99, cross‑sectional study OR 1.19, 95%CI 1.13–1.26) and there was weak evidence of a positive 
association with aggressive disease (OR 1.03, 95%CI 1.00–1.06). There was also weak evidence of 
a small inverse association of adiponectin with overall prostate cancer (OR 0.96, 95%CI 0.93–0.99, 
per 2.5 µg/ml increase), but less evidence of an association with aggressive disease (OR 0.98, 95%CI 
0.94–1.01). The magnitude of any effects are small, therefore levels of circulating adiponectin or leptin 
alone are unlikely to be useful biomarkers of risk or prognosis.
Abbreviations
BMI  Body Mass Index
IGF  Insulin-like Growth factor
OR  Odds ratio
CI  Confidence interval
PSA  Prostate-specific antigen
ELISA  Enzyme immunoassay
RIA  Radioimmunoassay
MAP  Multi-analyte processing
LTIA  Latex particle-enhanced turbidimetric immunoassay
Prostate cancer is a cause of considerable morbidity and mortality, particularly in industrialised countries where 
obesity is  epidemic1,2. Although over 60% of men aged 85 have histological evidence of prostate  cancer3, the 
disease is often indolent and most affected men will die of other causes before the cancer  progresses4. Identi-
fication of markers of aggressive disease is imperative to recognising those cancers likely to progress, enabling 
radical treatment to be reserved for high-risk cases and minimising morbidity from unnecessary  treatments5,6. 
In meta-analyses of observational studies, body mass index (BMI) is associated with a modest increased risk of 
advanced and fatal prostate cancer, and of biochemical recurrence (8–21% increase in risk per 5 kg/m2 increment 
in BMI)7–9. However, Mendelian randomisation analysis did not find genetic variants associated with increased 
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BMI to be associated with risk of advanced or high grade disease but did find weak evidence of an association 
with lower prostate cancer  risk10.
Biologically-active polypeptides synthesised and secreted by white adipose tissue, adipokines, may medi-
ate the association between obesity and prostate cancer progression. In vitro, leptin stimulates growth factor 
 expression11,  proliferation12, androgen-independent cells  migration13 and expresses angiogenic  properties14, 
while adiponectin inhibits prostate cancer cell  proliferation15 and  angiogenesis16. We hypothesise that leptin is 
positively associated with risk of overall and aggressive prostate cancer and adiponectin is inversely associated 
with risk of overall and aggressive prostate cancer. Here we systematically review the epidemiological evidence 
on associations of circulating adiponectin and leptin with overall and aggressive (higher grade and/or more 
advanced stage) prostate cancer and combine study-specific effect estimates in a dose–response meta-analysis.
Methods
Search strategy. Studies in humans of associations of circulating adiponectin and/or leptin with pros-
tate cancer prevalence, incidence, stage, grade, mortality or other measures of aggressive prostate cancer were 
identified through systematic searches of the bibliographic databases Medline (1950-April 1st 2017), Embase 
(1980-April 1st 2017) and Web of Science (1899-April 1st 2017). A comprehensive combination of MeSH and 
text words was used to search the databases (Supplementary Table S1) and no language restrictions were applied. 
Reference lists of the articles selected for inclusion in the meta-analysis and of related articles, particularly 
reviews, were searched by hand.
Inclusion and exclusion. Abstracts were screened and excluded if they were: genetic studies, animal stud-
ies, cell culture or biochemical studies, if they did not report on associations of adiponectin or leptin with pros-
tate cancer, or if they did not contain original data (i.e. were review papers and/or commentaries). For the 
remaining studies and those for which eligibility was unclear, full articles were retrieved and assessed for inclu-
sion by two reviewers independently (AB, and KT, RMM or RL). Studies were eligible for inclusion if they: pre-
sented original peer-reviewed data, included measures of adiponectin and/or leptin in human blood, included 
data from men with prostate cancer and included a comparison group (for overall prostate cancer incidence this 
was cancer-free men and for aggressive prostate cancer incidence this was either men without cancer or with low 
risk prostate cancer). Cohort, nested case–control and retrospective case–control studies were eligible. Duplicate 
publication of study results was identified by comparing study locations, authors, study names, descriptions of 
the study population, recruitment dates and study designs. Where results were published more than once, the 
paper which included the highest number of cases, the most detail or the most comparable estimate was selected 
for inclusion.
Data extraction. Data at the level of the study (e.g. year of publication, author, study type) and the result (e.g. 
estimate type, number of cases and controls, covariates included) were extracted using a standardised extraction 
form by one author (AB or RL) and check by another (RB). If data necessary to derive a dose–response odds ratio 
(OR) were not extractable (risk estimate not given, risk estimate scale not given, or the distribution of adiponec-
tin or leptin levels not given), study authors were contacted for further details.
Statistical analysis. To combine data across studies, study-specific estimates were converted to log OR per 
2.5 unit (ng/ml for leptin and µg/ml for adiponectin) increase in adiponectin or leptin. These ‘dose–response’ 
ORs were pooled in a meta-analysis, separately for overall prostate cancer risk and risk of aggressive disease 
(defined as high grade, advanced stage, high volume, a combination measure and/or fatal prostate cancer). A 
2.5 unit increase was selected as this represents approximately one quarter of the adiponectin or leptin distribu-
tion and a 2.5 ng/ml increase in leptin corresponds to around a 5 kg/m2 increase in BMI (calculated from the 
distribution in the Prostate Testing for Cancer and Treatment  study17. The limited number of studies identified 
prevented the possibility of assessment of non-linear associations.
Results were reported in three main forms, each of which required a different method of conversion. Firstly, if 
the difference in means or medians between cases and controls was reported, this was converted to dose–response 
ORs using the method described by Chêne and Thompson, which assumes an approximately normal distribution 
of  exposure18. Secondly, if the ORs per quantile of adiponectin or leptin were reported, a dose–response OR was 
derived using the Greenland and Longnecker  method19. For this method, a mean or median of the exposure 
in each quantile and the number of cases and controls in each quantile, were needed; if neither of these were 
reported, the mean in each group was estimated using the  range18. Thirdly, if the odds ratio per (x) units increase 
in exposure was given, the OR per 1 unit was calculated by 1 − ((1 − OR)/x). Following conversion to a log odds 
ratio, this was then multiplied by 2.5 to give the log odds ratio per 2.5 units.
Two primary meta-analyses were carried out for each exposure: (i) a pooled estimate of the log OR of overall 
prostate cancer risk per 2.5 unit increase in adiponectin or leptin; and (ii) a pooled estimate of the log odds ratio 
of aggressive prostate cancer per 2.5 unit increase in adiponectin or leptin. Analyses were stratified by study 
design; if blood draw was at any time point before biopsy this was considered prospective (including diagnostic 
PSA tests, 5 studies), and if after biopsy, as cross-sectional. If a paper presented more than one type of result, 
or more than one logistic regression result (i.e. minimally adjusted and multivariable adjusted), all results were 
extracted but the results were selected for inclusion in the main analyses using the following order of priority: 
(A) the effect estimate was: (i) a dose–response OR, (ii) a categorical/quantile OR, (iii) the median or mean dif-
ference between cases and controls; (B) the estimate was adjusted for: (i) age only (minimally adjusted as these 
were more comparable between studies), (ii) hormones/smoking/BMI (maximally adjusted); (C) the measure of 
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aggressiveness was: (i) grade (most commonly reported and therefore was most comparable between studies); 
(ii) stage; (iii) another measure (such as high volume disease, mortality or a combination measure).
As weights applied in fixed-effects analyses are more proportional to the size of the study, the primary analyses 
were based on the fixed effects estimates, although random effect estimates (which generally give more conserva-
tive estimates than fixed effects estimates but give more weight to smaller  studies20) were also calculated and 
presented for completeness. The  I2 statistic was calculated to quantify the percentage of between-study variation 
due to  heterogeneity21,22; an  I2 of 0% indicates the true association is the same between studies. The larger the 
 I2 the higher the proportion of the total variation in study estimates is due to between-study variability and not 
sampling error, indicating that the true association differs between  studies22.
Subgroup analyses of the main results were used to explore potential sources of heterogeneity: (i) the origi-
nal results format used to derive the dose–response OR (mean difference or odds ratio)); (ii) the assay method 
(ELISA, RIA or another)); (iii) the measure of prostate cancer aggressiveness (grade, stage, other/combined); (iv) 
the mean study-level BMI (< or ≥ 27kgm2) ; and v) the method of prostate cancer detection i.e. whether non-PSA 
screen (clinically) detected or detected by PSA-screening. If studies did not specifically report whether cases 
were PSA or clinically detected, they were classified as method ‘not reported’, apart from those with high mean 
PSA levels amongst cases or those where cases were sampled before the PSA screening era, which were classi-
fied as non-PSA screen detected. Where reported, we extracted effect-estimates stratified by BMI (usually < 25 
and ≥ 25kgm2). We also assessed heterogeneity by factors that could affect susceptibility to bias, as there is not 
a single generally accepted quality assessment tool for observational  studies23: study design (prospective versus 
cross-sectional data collection, as defined above); adjustment for confounding (including maximally adjusted 
models over minimally adjusted models); and type of effect-estimate (comparing pooled OR estimates to pooled 
mean difference estimates).
Sensitivity analysis and publication bias. We conducted sensitivity analyses where: (i) advanced stage 
was selected over other measures of aggressive disease and over high grade; (ii) maximally adjusted estimates 
were selected over minimally adjusted and (iii) both (i) and (ii). Some prospective studies drew blood around 
the time of diagnosis, at which point the cancer would have already been present which may affect adiponectin 
or leptin levels (reverse causality). To examine the effect of time of blood draw relative to diagnosis prospec-
tive studies were plotted by time of blood draw and an additional sensitivity analysis redefining prospective 
as > 1  year pre-diagnosis was conducted. An influence analysis, in which each study was excluded from the 
pooled estimate systematically, was conducted to gauge the influence of individual studies on pooled estimates. 
Small study effects were explored using funnel  plots24 and tests of funnel plot asymmetry (the Egger and the 
Begg tests)25; as these tests can produce false-positive results when analysing odds  ratios25, manual inspection of 
funnel plots was used as the main indicator of publication bias.
The search was updated to October 2018 to identify if any further studies had been published after the end 
of the study period. These further studies, plus those from the earlier search which could not be included in the 
main analyses, had minimal statistical information (the P value, sample size and direction of effect) extracted 
and plotted alongside the main results in an albatross plot. Albatross plots allow an approximate estimation of 
underlying effect sizes and can potentially identify sources of heterogeneity in results from systematic reviews 
where limited comparable data are  available26.
All analyses were conducted in Stata (StataCorp. 2013. Stata Statistical Software: Release 13.1. College Station, 
TX: StataCorp LP). The protocol for the review was registered in the PROSPERO international prospective regis-
ter of systematic reviews: (http://www.crd.york.ac.uk/PROSP ERO/displ ay_recor d.php?ID=CRD42 01707 4010).
Results
Characteristics of included studies. 746 potentially eligible studies were identified, 610 were clearly 
ineligible (they were genetic, in vivo, in vitro or biochemical studies, reviews, commentaries or duplicates or 
did not report on the associations of adiponectin or leptin with prostate cancer) therefore 137 publications were 
retrieved. 34 studies fulfilled the inclusion criteria (Fig. 1). The authors of 15 of these were contacted to request 
further information and 9 responded and supplied additional data. Given the available data, we were able to 
derive dose–response ORs from all but 1  study27. In one small study (9 cases)28 the derived OR for the associa-
tion between adiponectin and aggressive prostate cancer was implausibly small (0.02, 95% CI 0.00 to 0.13) and 
this estimate was excluded (but the effect estimate from this study for the association between adiponectin and 
overall prostate cancer was included). In another study it was unclear what measure of dispersion around the 
mean was reported and assuming either standard error or standard deviation resulted in implausibly narrow 
confidence intervals or small effect estimate, respectively. As it was unclear which, if either, was correct this study 
was  excluded29.
Reported adipokine levels fell outside of the physiological range (3 to 30 μg/mL for  adiponectin30 and 1 to 
30 ng/ml for  leptin31) in 7 studies of adiponectin and 1 of leptin. Adiponectin requires a dilution before analysis 
and it appeared five studies either failed to back-adjusted results for this dilution factor or erroneously reported 
results in ng/ml rather than µg/ml. When contacted, authors of two out of the five  studies32,33 stated the former 
was most likely; there was no response from the remaining three  studies29,34,35. When an adjustment for dilu-
tion factor (1:500) was made the results fell into the physiological range and these adjusted results were used in 
analyses. One study gave no  units36 but when contacted the authors stated the units should be ng/ml. These results 
fell out of the physiological range, even after assuming this was an error and therefore this study was excluded. 
Another adiponectin study reported results in pg/ml, which the authors stated was a typographical  error37. The 
leptin study reported results in pg/ml and when contacted the author no longer had access to the  data38. This 
was assumed to be a typographical error also.
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The final meta-analysis included 31 studies (Fig. 1)17,28,32–35,37–61, 19 studies investigated adiponectin (9 pro-
spective, 10 cross-sectional) and 21 investigated leptin (11 prospective, 10 cross-sectional) (Table 1). The main 
leptin meta-analyses included 4343 incident prostate cancer cases and 1486 aggressive prostate cancer cases. 
The main adiponectin meta-analyses included 1550 incident prostate cancer cases and 1334 aggressive prostate 
cancer.
There were more studies from the USA (n = 13) than any other country (n = 18) and, despite a wide geographi-
cal distribution including Asia, Europe, South and North America, most participants were white (see Table 1). 
Studies ranged from 7 to 1314 prostate cancer cases (mean 153). The average age of the men studied was 60 to 
65 years. All but two studies measured adiponectin and leptin by the conventional methods of enzyme immu-
noassay (ELISA) or radioimmunoassay (RIA). One study used multi-analyte processing (MAP)  technology38 
and another latex particle-enhanced turbidimetric immunoassay (LTIA)50.
Figure 1.  Flow diagram of study selection.
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Arisan39, 2007 Cross-sectional Turkey NS
8 men with high 
grade (Gleason 
score ≥ 8) PCa
10 with low 
grade (Gleason 




















Total PCa: 125 
men with PCa
Aggressive 
PCa: 40 men 
with high 
grade (Gleason 




men with low 
grade (Gleason 
score ≤ 6) PCa
Mean 1.43 (SD 
1.29) years 
before diagnosis




Adjusted for age 
and race. Inverse 
normal used to 
estimate distri-
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from distribu-
tion in control. 
Assumed the 
units for leptin 
should be ng/ml
Basaria40, 2005 Cross-sectional USA NS




18 men with 
metastatic PCa 
treated with RP 
or radiotherapy


















416 men with 
high grade 
(Gleason 
score ≥ 7) PCa
307 men with 
low grade (Glea-





A, L (ELISA, 
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increase)
Adjusted for age, 
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assay run
Chang41, 2001 Cross-sectional USA White
150 men with 
high volume 
(> 0.5 cc) PCa 
or extraprostatic 
extension
44 men with 
low volume 
(< 0.5 cc) PCa
After diagnosis L (ELISA, Linco)
Mean Differ-
ence
Di  Sebastiano42, 
2016 Cross-sectional Canada NS
8 men with 
aggressive PCa 
(Gleason ≥ 8, 
PSA > 20 ng/dl 
or stage > T3A
9 healthy men After diagnosis A, L (ELISA, R&D Systems)
Mean Differ-
ence
Matched for age 
and BMI
Di  Sebastiano37, 
2017 Cross-sectional Canada NS
Total: 38 with 
PCa
Aggressive 21 
men with high 
grade (Glea-




men with low 
grade (Glea-
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At (n = 36) or 
after (n = 15) 
diagnosis













88.8% of high 
grade cases, 
88.4% of low 
grade cases 
and 89.1% of 
controls White
Total: 95 men 




men with high 
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137 biopsy-
negative men
After referal for 
biopsy, before 
diagnosis















97% white, 2% 
black, 1% other




149 men with 
T1c stage PCa
After diagnosis, 





97% white, 2% 
black, 1% other
65 men with 
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score ≥ 7) PCa
171 men with 
low grade (Glea-
son score ≤ 6) 
PCa
After diagnosis, 
before RP A (ELISA, NS)
Categorical OR 
(quartiles)
Adjusted for age. 
Inverse normal 
used to estimate 
distribution 






volu45, 2006 Cross-sectional USA NS
55 men with 










A (RIA, Linco) Mean Differ-ence
SDs were calcu-
lated from the 
p for difference. 
Aggressive PCa 
results could not 
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Age and BMI 
matched. SD 
estimated from p 
for difference
Gu47, 2014 Cross-sectional China 100% Chinese Han
305 men with 





Matched for age 
and urban/rural 
residence
Gu60, 2015 Cross-sectional China 100% Chinese Han
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of Gu 2014
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Housa33, 2008 Cross-sectional Czech Republic NS
Total: 43 men 
with T2 stage 
PCa
Aggressive: 16 
men with high 
grade (Gleason 
score ≥ 7) PCa
Total: 25 men 
with BPH
Aggressive: 27 
men with low 
grade (Gleason 
score ≤ 6) PCa
After diagnosis, 




from ng/ml to 
µg/ml (author 
said results were 
not adjusted for 
dilution factor)




L (RIA, Linco) Categorical ORs (tertiles) Adjusted for age
Ikeda50, 2015 Prospective Japan NS
Total: 24 men 
with PCa
Aggressive 
8 men with 
high risk PCa 
(D’Amico clas-
sification)
Total: 2817 men 
with PSA < 4 ng/
ml
Aggressive: 16 
men with low 
or intermedi-













Lagiou51, 1998 Cross-sectional Greece NS 43 men with PCa 48 healthy men After diagnosis L (RIA, Linco)
OR per 4 ng/














94.2% of cases 
and 92.9% of 
controls white
1314 men who 
developed PCa
1314 men who 












Matched on age, 
PSA test pre 
blood draw, year, 
time of day and 







Total: 635 men 




men with high 
grade (Gleason 
score ≥ 8) 










men (115 in 
adiponectin 
analysis)
Up to 18 years 
before diagnosis




Matched on and 
adjusted for age 
and smoking 
status
López  Fontana34, 
2011 Cross-sectional Argentina NS
Total: 35 men 
with PCa
Aggressive: 23 
men with high 
grade (Gleason 
score ≥ 7) PCa
Total: 35 healthy 
men
Aggressive: 12 
men with low 
grade (Gleason 
score ≤ 6) Pca




plied by author. 
Units converted 
from ng/ml to 
µg/ml
Michalakis35, 
2007 Cross-sectional Greece NS
75 men with 
PCa 150 healthy men After diagnosis A (RIA, Linco)
Categorical OR 
(quartiles)
Adjusted for age. 
Units converted 
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In main analyses, cases in studies of overall prostate cancer incidence were mostly a mix of men with aggres-
sive and non-aggressive prostate cancer although four studies included men with low  grade43,53, non-metastatic40, 
or stage  T233 prostate cancer only. Controls were healthy men (17 studies), men with BPH (1 study) or a mixture 
of both (4 studies). Cases in studies of aggressive prostate cancer were men with high grade (Gleason score ≥ 7 
or ≥ 8, 13 studies), higher stage (T2-3 or metastatic, 1 study), high volume (1 study), high risk ‘D’Amico’ clas-
sification (1 study), biochemical recurrence after prostatectomy (1 study) or a combination score (defined by 
either high Gleason score, advanced TNM stage, high PSA level or fatal disease, 3 studies). Controls in studies 
of aggressive prostate cancer were men with prostate cancer who did not fall into the above categories (i.e. Glea-
son ≤ 6 or ‘non-aggressive’), except for 5 studies in which controls were healthy men.
Leptin. For leptin and overall prostate cancer, the overall fixed effect OR was consistent with the null hypoth-
esis (OR 1.00, 95% CI 0.98 to 1.02 per 2.5 ng/ml increase in leptin, p = 0.84) (Fig. 2a). However, there were 
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7.1% black, 6.8% 
other
Total: 1224 men 
with low grade 
(Gleason ≤ 6) 
PCa
Aggressive: 486 
men with high 
grade (Gleason 














arm & family 
history matched. 
Adjusted for 
age, race, family 





Saglam54, 2003 Cross-sectional Turkey NS
Total: 21 men 
with PCa
Aggressive: 7 
men with high 
grade (Gleason 
score ≥ 8) PCa
Total: 50 healthy 
men
Aggressive: 9 






L (RIA, Linco) Mean Differ-ence
SDs were calcu-
lated from the p 
for difference
Sher55, 2008 Cross-sectional USA 94% white, 4% black, 2% other
253 men with 
High grade 
(Gleason 
score ≥ 7) PCa
286 men with 
Low grade 
(Gleason 









Singh56, 2010 Cross-Sectional India South Asian
Total: 30 men 
with PCa
Aggressive: 7 
men with high 
grade (Gleason 
score 7) PCa
Total: 30 healthy 
men
Aggressive: 23 
men with low 
grade (Gleason 
score ≤ 6) PCa










272 men with 
aggressive 
prostate cancer 
(≥ Gleason score 
7, stage T3 or 
T4 at diagnosis 
and/or fatal PCa
272 healthy men Up to 9 years before diagnosis




Matched on date 
















Total: 392 men 
with PCa
Aggressive: 
114 men with 
aggressive 
(Gleason 
score ≥ 8, T3-4, 
N1 or M1, 
PSA > 50 ng/ml 
or fatal disease) 
PCa
392 healthy men






























NS 156 men who developed PCa 312 healthy men
Up to 13 years 
before diagnosis




Matched on age, 
BMI and inter-
vention group
Table 1.  Study characteristics. * For estimate used in the main analyses. PCa prostate cancer; ELISA enzyme-
linked immunoassay; RIA radioimmunoassay; MAP multi-analyte profiling; LTIA latex particle-enhanced 
turbidimetric immunoassay; A adiponectin; L leptin; NS not stated; RP radical prostatectomy; BMI body mass 
index; IGF-I insulin-like growth factor I; BPH benign prostatic hyperplasia.
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CI 0.95 to 0.99, p = 0.005) per 2.5 ng/ml increase in leptin, whereas that for cross-sectional studies was 1.19 (95% 
CI 1.13 to 1.26, p < 0.001). (Meta-regression p for difference in random effects estimates by study type p = 0.001). 
There was evidence of moderate heterogeneity amongst estimates from prospective studies  (I2 = 54.9%) and 
cross-sectional studies (52.5%); therefore, pooling of individual study estimates may not be appropriate and 
these results should be interpreted cautiously.
There was weak evidence of a small association between leptin and aggressive prostate cancer (Fig. 2b, overall 
OR 1.03, 95% CI 1.00 to 1.06 per 2.5 ng/ml increase in leptin, p = 0.02). However, there was considerable hetero-
geneity amongst cross-sectional studies  (I2 = 83.6%) for which the effect estimate was larger (pooled OR: 1.09 
(95% CI 1.03 to 1.16), p = 0.004) than for prospective studies (OR: 1.02 (95% CI 0.99 to 1.05), p = 0.23,  I2 0.0%). 
(Meta-regression p for difference in random effects estimates by study type p = 0.27).
Adiponectin. For adiponectin and overall prostate cancer, the overall pooled estimate indicated a small 
(4%) decreased risk of prostate cancer per 2.5 µg/ml increase in adiponectin (OR 0.96, 95% CI 0.93 to 0.99 per 
2.5 µg/ml increase in adiponectin, p = 0.01) (Fig. 2c); the association was stronger in cross-sectional studies (OR 
0.89, 95%CI 0.83 to 0.95, p = 0.001) than prospective studies (OR 0.98, 95% CI 0.95 to 1.01, p = 0.17,  I2 = 46.9%), 
though there was considerable heterogeneity amongst the former  (I2 = 76.0%). (Meta-regression p for difference 
in random effects estimates by study type p = 0.26).
Overall, there was little evidence of an association between adiponectin and aggressive prostate cancer (OR 
0.98, 95%CI 0.94 to 1.01, p = 0.16, Fig. 2d). The pooled OR for cross-sectional studies was 0.97, 95% CI 0.93 to 
1.02, p = 0.29,  I2 = 62.6%. Most small (< 30 cases) cross-sectional studies found evidence that adiponectin was 
inversely associated with risk of aggressive prostate cancer, but larger studies did not. The prospective study 
estimates were more centred around the null with less evidence of heterogeneity (pooled OR 0.98 (95%CI 0.94 
to 1.02, p = 0.33,  I2 = 29.6%). (Meta-regression p for difference in random effects estimates by study type p = 0.34).
Sensitivity analyses. The sensitivity analyses indicted that the pooled estimates were not sensitive to the 
majority of factors investigated (Supplementary Table S2). However, the weak association of leptin with aggres-
sive prostate cancer was attenuated when maximally adjusted models were selected over minimally adjusted 
models. Redefining prospective as blood draw greater than one year before diagnosis did not change prospective 
study estimates. (Additionally, when stratified, there were no differences in pooled estimates from ‘diagnostic’ 
prospective studies compared to those where blood draw was greater than one year before diagnosis).
There was little evidence of funnel plot asymmetry in studies of associations of adiponectin or leptin with 
prostate cancer incidence (Fig. 3). However, there was some evidence of asymmetry in studies of aggressive 
prostate cancer; for leptin this asymmetry was to the right, or towards positive associations in smaller studies, 
and for adiponectin this was to the left, or towards inverse associations in smaller studies. These observations 
were supported by the Egger and Begg test results (p = 0.033 and p = 0.048 respectively for leptin and p = 0.019 
and p = 0.029 respectively for adiponectin and aggressive prostate cancer).
Influence analysis. In an influence analysis (Table 2), the overall results appeared relatively stable, particu-
larly for prospective study pooled estimates. Exceptions are discussed. For leptin and prostate cancer incidence, 
exclusion of the study by Stocks et al.58) decreased the heterogeneity amongst prospective studies (from 54.9% 
to 27.4%) but slightly attenuated the affect estimate from 0.97 (0.95–0.99) to 0.98 (0.95–1.00). For leptin and 
aggressive prostate cancer, cross-sectional study estimates were affected by exclusion of Basaria et  al.40: this 
attenuated the association from 1.09 (1.03–1.16) to 1.04 (0.97–1.12); and Freedland et al.44: this increased the 
estimate to 1.17 (1.09–1.25).
For adiponectin and prostate cancer incidence, exclusion of one study by Lopez Fontana et al.34 reduced 
heterogeneity amongst cross-sectional studies from 76.0% to 47.9% but did not materially change the effect 
estimate. Exclusion of Goktas et al.28 attenuated the effect estimate from 0.89 (0.83–0.95) to 0.95 (0.85–1.06). 
In studies of aggressive prostate cancer, exclusion of Arisan et al.39 from cross-sectional study analyses did not 
affect the pooled estimate but reduced heterogeneity from 62.6% to 10.2%.
Subgroup Analyses. Subgrouping analyses resulted in small numbers in groups so results are interpreted 
with caution (Supplementary Tables S3 and S4). Prospective studies were more likely to report odds ratios and 
cross-sectional studies mean differences. Stratification of studies by estimate type or assay type did not have a 
consistent effect on pooled estimates and estimates remained relatively consistent with the main findings. Where 
stage was reported as an outcome these results were pooled and compared to those for grade. For studies of 
leptin, a positive association with high grade, but not advanced stage, was seen. For studies of adiponectin, esti-
mates were closer to the null for studies of stage than of grade. Prospective studies were more likely to report case 
detection by PSA screening; no cross-sectional studies reported case detection by PSA screening. Estimates were 
not different between those that were and were not screen-detected. However, where the PSA-screening status of 
patients was unclear, estimates were somewhat different to those from screen-detected or non-screen-detected 
men, possibly as this was a marker of the quality of study reporting.
Pooled effect estimates from studies of leptin or adiponectin did not appear to vary substantially when 
stratified by study-level mean BMI (Supplementary Fig. S1). There was little evidence of an interaction by mean 
study-level BMI (meta-regression p for difference in random effects estimates by mean BMI was > 0.3 in each 
main analysis).
Those studies that conducted BMI-stratified analyses (N = 7), did not provide evidence that the association 
of leptin with prostate cancer incidence or progression varied by BMI. None of the included studies examined 
adiponectin and prostate cancer incidence associations stratified by BMI. Two out of three studies that examined 
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Figure 2.  Forest Plots. (a) Forest plot of associations of leptin with total prostate cancer incidence (OR per 
2.5 ng/ml increase in leptin) by study design. (b) Forest plot of associations of leptin with aggressive prostate 
cancer (OR per 2.5 ng/ml increase in leptin) by study design. (c) Forest plot of associations of adiponectin with 
total prostate cancer incidence (OR per 2.5 µg/ml increase in adiponectin) by study design. (d) Forest plot of 
associations of adiponectin with aggressive prostate cancer (OR per 2.5 µg/ml increase in adiponectin) by study 
design. Notes Ordered by date (cross-sectional studies) or mean time from blood draw to diagnosis (prospective 
studies). Weight for fixed-effects model.
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BMI-stratified associations of adiponectin with advanced stage or fatal prostate cancer found an inverse asso-
ciation in overweight men only (OR of advanced stage per log adiponectin unit in those with a BMI < 25: 1.48 
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adiponectin compared to lowest quintile in those with BMI < 25: 0.86 (95%CI 0.31–2.38) and in those with 
BMI ≥ 25: 0.10 (95%CI 0.01–0.78), p for interaction 0.0861.
The search was updated to October 2018 and 103 new articles matching search criteria were identified. The 
abstract screen revealed 83 were ineligible (e.g. in vitro, genetic studies), and a further 15 were trials with no 
control groups, repeat publications or abstracts. 5 studies were  eligible62–66. The albatross  plots26 in Supplemen-
tary Fig. S2 indicate no strong consistent effects in either direction, with larger studies clustered around the null 
(no association) and smaller studies reporting smaller p values (stronger associations). For leptin, these small 
study effects were in the direction of a positive association and for adiponectin a negative association. There is 
no obvious bias from exclusion of these studies.
Discussion
No strong, consistent associations between adipokines levels and risk of incident or aggressive prostate cancer 
were found. Pooled effect estimates from cross-sectional studies tended to be larger, more heterogenous and less 
stable to sensitivity analyses than those from prospective studies. When just the prospective evidence was con-
sidered, all pooled effect estimates were consistent with the null hypothesis accept for a weak inverse association 
between leptin and overall prostate cancer (3% decreased risk per 2.5 ng/ml increase in leptin).
A mainly qualitative systematic review of adiponectin, leptin and ghrelin levels with prostate cancer incidence 
and advanced disease was recently  published67. It included a small exploratory meta-analysis and, in general, 
their findings corresponded with ours. However, they reported some suggestive evidence of an inverse associa-
tion between adiponectin and advanced prostate cancer (meta relative risk 0.81 (95%CI 0.61–1.08) comparing 
the highest subset of adiponectin). This was based on 4 nested case–control studies, one which was included 
twice. Our pooled effect estimate for adiponectin and aggressive prostate cancer, which was derived from 7 
prospective and 7 cross-sectional studies, did not indicate evidence of an inverse dose–response association 
(OR 0.98, 95%CI 0.94–1.01). A meta-analysis of genetic polymorphisms in adiponectin, leptin and their recep-
tors found several associations with prostate cancer risk and  aggressiveness68. Although this provides evidence 
that adipokine signaling may be involved in prostate carcinogenesis, the analyses were limited by the number 
of studies included. Additionally, studies of circulating adipokines in the general populations cannot exclude 
the possibility that adipokines may be associated with prostate cancer in certain subgroups of the population, 
such as those with particular metabolic profiles, or through local paracrine signalling of adipokines due to the 
abundance of periprostatic adipose tissue.
Relevant case-control studies nested within the San Antonio Center for Biomarkers of Risk of Prostate Cancer 
cohort study were reported in two papers. Baillargeon et al.38 included fewer cases and controls but examined 
both leptin and adiponectin, measured by multi-analyte profiling. Medina et al.69 focused on adiponectin mul-
timers, measured by ELISA. They found only high-molecular weight adiponectin was associated with prostate 
cancer incidence (but not total, middle- or low-molecular weight adiponectin). The decision was taken to include 
Figure 3.  Funnel plots of included papers; adiponectin and leptin with incident or aggressive prostate cancer.
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the former as it was deemed more comparable with the other studies, but inclusion of the later would not have 
altered the results.
Limitations. Many studies were small and quality of reporting was variable. There was considerable hetero-
geneity amongst study estimates, particularly cross-sectional evidence, indicating the true effect estimates may 
vary between studies. Confounding and selection bias are inherent issues in observational data; as a result meta-
Table 2.  Influence analysis. Studies were sequentially excluded and analyses repeated. Pooled fixed-effects 
odds ratios. ORs per 2.5 ng/ml increase in leptin or 2.5 μg/ml increase in adiponectin. OR odds ratio; LCI 
lower confidence interval; UCI upper confidence interval; NA not applicable.
Prostate cancer incidence Aggressive prostate cancer
OR LCI UCI Weight P* I2 (%) OR LCI UCI Weight P* I2 (%)
Cross-sectional Cross-sectional
Leptin
All studies 1.19 1.13 1.26 14.3  < 0.001 52.5% All studies 1.09 1.03 1.16 19.1 0.004 83.6%
Excluding Excluding
 Lagiou, 1998 1.20 1.14 1.27 14.1  < 0.001 52.9%  Chang, 2001 1.07 1.00 1.14 17.1 0.06 84.3%
 Hsing, 2001 1.19 1.12 1.26 13.7  < 0.001 56.0%  Saglam, 2003 1.08 1.01 1.14 18.8 0.02 80.1%
 Saglam, 2003 1.19 1.11 1.26 11.4  < 0.001 59.6%  Basaria, 2005 1.04 0.97 1.12 13.7 0.25 84.4%
 Basaria, 2005 1.19 1.12 1.26 13.5  < 0.001 59.2%  Freedland, 2005 1.17 1.09 1.25 15.7  < 0.001 75.4%
 Gade-Andavolu, 2006 1.17 1.10 1.24 12.4  < 0.001 47.3%  Arisan, 2007 1.09 1.02 1.15 18.9 0.007 84.7%
 Singh, 2010 1.24 1.15 1.34 7.9  < 0.001 54.5%  Singh, 2010 1.13 1.05 1.21 14.5 0.001 85.0%
 López Fontana, 2011 1.21 1.14 1.28 13.8  < 0.001 29.7%  López Fontana, 2011 1.08 1.02 1.15 18.8 0.009 84.9%
 Di Sebastiano, 2016 1.09 1.03 1.16 18.8 0.004 86.0%
Prospective Prospective
All studies 0.97 0.95 0.99 85.8 0.005 54.9% All studies 1.02 0.99 1.05 81.0 0.23 0.0%
Excluding Excluding
 Baillargeon, 2006 0.97 0.95 0.99 84.0 0.01 60.3%  Baillargeon, 2006 1.02 0.99 1.05 80.6 0.25 0.0%
 Stocks, 2007 0.98 0.95 1.00 85.2 0.03 27.4%  Stocks, 2007 1.02 0.99 1.05 80.6 0.26 0.0%
 Li, 2010 0.96 0.94 0.99 84.3 0.002 54.5%  Li, 2010 1.02 0.99 1.05 80.4 0.33 0.0%
 Neuhouser, 2010 0.98 0.95 1.01 76.0 0.26 56.2%  Neuhouser, 2010 1.01 0.97 1.05 70.6 0.56 0.0%
 Touvier, 2012 0.97 0.95 0.99 85.6 0.004 60.1%  Burton, 2013 1.02 0.99 1.05 78.2 0.19 0.0%
 Fowke, 2013 0.96 0.94 0.98 83.2 0.001 49.2%  Fowke, 2013 1.03 0.99 1.06 74.5 0.14 0.0%
 Lai, 2014 0.97 0.95 0.99 85.6 0.009 56.0%  Di Sebastiano, 2017 1.02 0.99 1.05 80.7 0.27 0.0%
 Gupta, 2016 0.97 0.95 0.99 85.5 0.004 59.1%
 Di Sebastiano, 2017 0.97 0.95 0.99 85.6 0.004 58.0%
Adiponectin
All studies 0.89 0.83 0.95 17.5 0.001 76.0% All studies 0.97 0.93 1.02 43.0 0.29 62.6%
Excluding Excluding
 Goktas, 2005 0.95 0.85 1.06 8.2 0.34 79.1%  Freedland, 2005 0.98 0.93 1.03 42.2 0.39 67.1%
 Michalakis, 2007 0.91 0.84 0.98 16.5 0.01 71.6%  Arisan, 2007 0.98 0.93 1.03 42.7 0.51 10.2%
 Housa, 2008 0.89 0.82 0.96 16.7 0.002 82.0%  Sher, 2008 0.88 0.79 0.97 14.6 0.02 55.4%
 López Fontana, 2011 0.85 0.79 0.92 15.7  < 0.001 47.9%  Housa, 2008 0.98 0.93 1.03 42.5 0.37 66.8%
 Gu, 2014 0.88 0.81 0.95 15.0 0.001 81.3%  López Fontana,  201127 0.98 0.93 1.03 42.4 0.40 65.4%
 Gu, 2015 0.97 0.92 1.03 39.7 0.30 68.8%
 Di Sebastiano, 2016 0.98 0.93 1.03 42.9 0.34 66.1%
Prospective Prospective
All studies 0.98 0.95 1.01 82.5 0.17 46.9% All studies 0.98 0.94 1.02 57.0 0.33 29.6%
Excluding Excluding
 Baillargeon, 2006 0.97 0.94 1.01 76.8 0.20 55.5%  Baillargeon,  2006 0.97 0.93 1.02 56.4 0.23 18.8%
 Grosman, 2010 0.99 0.95 1.03 79.4 0.58 43.0%
 Li, 2010 0.99 0.95 1.02 78.9 0.46 51.3%  Li, 2010 0.99 0.94 1.03 55.2 0.60 18.5%
 Touvier, 2012 0.98 0.94 1.01 81.6 0.15 54.4%  Burton, 2013 0.97 0.92 1.02 46.1 0.23 37.6%
 Fowke, 2013 0.97 0.94 1.01 78.6 0.13 53.7%  Fowke, 2013 0.99 0.93 1.05 44.7 0.66 39.5%
 Ikeda, 2015 0.98 0.94 1.01 82.4 0.13 36.1%  Stevens, 2014 0.97 0.93 1.02 54.2 0.18 27.2%
 Di Sebastiano, 2017 0.97 0.94 1.01 82.1 0.09 28.5%  Ikeda, 2015 0.98 0.94 1.03 56.3 0.44 31.8%
 Di Sebastiano, 2017 0.98 0.94 1.03 56.3 0.43 34.6%
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analysis of such data risks producing spuriously precise pooled effect estimates (Egger et al. 2001) Consequently, 
it is recommended that the quantitative results should be interpreted with caution, and sources of heterogeneity 
thoroughly  explored70. However, the number of studies was too small, and the detail given in some reports insuf-
ficient, to explore heterogeneity adequately. There was heterogeneity in the definition of case and control groups; 
in particular, for aggressive prostate cancer. The majority used Gleason score as an outcome, although some 
included Gleason 7 as high grade and others did not—a matter that has been much debated in the literature. 
As a result of the mixture of outcome definitions, some studies may have included men with Gleason 7 in the 
comparison (‘non-aggressive’) group, potentially leading to an attenuation of any association. There was some 
evidence of possible reporting bias in studies of adipokines and aggressive prostate cancer, although there are 
other potential causes of funnel plot asymmetry such as poor study  methodology71. Non-linear trends could not 
be assessed due to the limited number and quality of studies. The detection of prostate cancer is complex and 
it is recognised that PSA-screening can result in over-diagnosis; we therefore performed a subgroup analysis in 
which studies based on PSA-screening were meta-analysed separately from those in which cancers were clini-
cally detected. However, several studies did not provide information on how cases were identified, preventing 
proper exploration of the effect of PSA-screening on associations.
Obesity or hormones such as insulin-like growth factor (IGF)-I may be on the causal pathway and therefore 
adjustment for such factors (mediators) could lead to over-adjustment. Adiposity may interact with the associa-
tion of adiponectin and leptin with prostate  cancer49; therefore, associations should ideally be examined sepa-
rately in normal weight and overweight men. This may be particularly important for associations of adiponectin 
with prostate cancer as adiponectin is an insulin-sensitising hormone and may have a more marked effect in 
men at higher risk of insulin  resistance17. Two out of three studies that did include analyses of adiponectin with 
aggressive prostate cancer stratified by BMI, found an inverse association with higher prostate cancer  stage17, 
and fatal prostate  cancer61, respectively, in obese and overweight men only. Medina et al.69 reported that the 
association of high-molecular weight adiponectin with prostate cancer incidence was adiposity dependent; posi-
tive in normal and overweight men and inverse in obese men. We further explored this by conducting subgroup 
analyses stratifying by the mean study-level BMI. We did not find further evidence to support this interaction 
with adiposity. Although an advantage of observational studies is that population subgroups often excluded from 
trials are more likely to be  included70, very few black men were studied. This is particularly important in prostate 
cancer, as black men are around 2–3 times more likely to develop the disease than white  men72. Therefore, this 
review cannot be considered representative of the wider population at risk.
Dose–response meta-analysis assumes a linear relationship between the exposure and outcome. The associa-
tion of adiponectin and leptin with prostate cancer stage may be U-shaped17 (possibly due to opposite patterns 
of association in overweight and normal weight men) and therefore such analysis may fail to detect an important 
association. The possibility of reverse causality in these studies (the disease state affecting adipokine levels) can-
not be excluded. Finally, and perhaps most importantly, observational data cannot identify causal associations 
because of the considerable possibility of confounding; any associations found may be markers of another, 
unmeasured, factor. For example, insulin resistance is a risk factor for prostate cancer and, as adiponectin is an 
insulin-sensitising hormone, levels are lower in men with insulin resistance.
Strengths. This review was not limited to English-only papers (although no non-English language papers 
were identified), or papers that reported one type of estimate. Several authors were contacted to request further 
information so their data could be included and the response rate to these requests was high. This is important 
as the strength of an association can affect the amount of detail reported and therefore the likelihood of being 
able to extract enough data to derive a dose–response OR, which can introduce bias. Our comprehensive search 
strategy and flexibility in deriving a dose–response OR from limited data will also have helped reduce this bias. 
Only 3 studies were excluded as the estimates could not be extracted or converted to a plausible dose–response 
OR. Stratification by point of data collection/study type (cross-sectional versus prospective) provided a means to 
explore the possibility of reverse causality. It appeared that for leptin in particular, reverse causality or selection 
bias is a possibility and prospective data may provide a more reliable estimate. Leptin and adiponectin are stable 
over at least 6 freeze thaw  cycles73,74. They exhibit slight diurnal variation but levels are relatively stable through-
out the day (reaching a nadir at night)75 and over time (the intra-class correlation coefficient derived from 4 
samples taken over 1 year was 0.74 for leptin and 0.81 for  adiponectin76. However, the variation associated with a 
single measure will tend to bias results towards the null; therefore, associations will not be overestimated.
Conclusion
We did not find strong evidence to support our hypotheses that leptin is positively associated with risk of overall 
and aggressive prostate cancer and adiponectin is inversely associated with risk of overall and aggressive prostate 
cancer. The weak evidence that leptin is inversely associated with overall prostate cancer risk reflects the findings 
of the Mendelian randomisation analysis of weak evidence of an association of BMI with lower prostate cancer 
 risk10, but it is not possible to know whether the association of BMI is mediated by leptin or leptin is purely a 
marker for high BMI. On an individual level, as a biomarker for detection or prognosis, adiponectin or leptin 
are unlikely to be useful as potential screening tools require exceptionally high ORs to give acceptable detection 
 rates77.
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